Baseline results of the Depiscan study: A French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR).
- Blanchon, Thierry
- Bréchot, Jeanne-Marie
- Grenier, Philippe,
- Ferretti, Gilbert,
- Lemarié, Etienne
- Milleron, Bernard
- Chagué, Dominique
- Laurent, François
- Martinet, Yves
- Beigelman-Aubry, Catherine
- Blanchon, François
- Revel, Marie-Pierre
- Friard, Sylvie
- Rémy-Jardin, Martine
- Vasile, Manuela
- Santelmo, Nicola
- Lecalier, Alain
- Lefébure, Patricia
- Moro-Sibilot, Denis
- Breton, Jean-Luc
- Carette, Marie-France
- Brambilla, Christian
- Fournel, François
- Kieffer, Alexia
- Frija, Guy
- Flahault, Antoine
- Depiscan, Group
DOIAbstract
BACKGROUND: Lung cancer has the highest mortality-rate per cancer, with an overall 5-year survival /=15 cigarettes per day for at least 20 years (former smokers having quit <15 years prior to enrollment). Based to randomization, annual LDCT or CXR screenings were planned at baseline and annually for 2 years. RESULTS: Between October 2002 and December 2004, 765 subjects were enrolled by 89 out of the 232 participating GPs and OPs. Complete clinical and imaging baseline data were available for 621 individuals out of the 765 enrolled, due to 144 noncompliant subjects who withdrew their consent. At least one nodule was detected in 152 out of 336 subjects (45.2%) in the LDCT screening, versus 21 out of 285 subjects (7.4%) in the CXR screening ar...
Add to ORKG